BMRN
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- BioMarin agreed to acquire Alesta Therapeutics to gain ALE1, a potential first oral therapy for hypophosphatasia, strengthening its clinical pipelineAug 18, 2026
- FDA accepted BioMarin's supplemental NDA seeking full approval of VOXZOGO for children with achondroplasiaJul 14, 2026
- BioMarin reports positive Phase 3 pivotal results for VOXZOGO in children with hypochondroplasiaMay 21, 2026
- BioMarin presents five-year Phase 3 results supporting long-term efficacy and safety of ROCTAVIAN® at ISTH 2025 CongressJun 25, 2025
- BioMarin presents new data on VOXZOGO® (vosoritide) in children with achondroplasia and other skeletal conditions at two international endocrinology meetings.May 12, 2025